16,937 reports of this reaction
11.1% of all DOCETAXEL ANHYDROUS reports
#1 most reported adverse reaction
ALOPECIA is the #1 most commonly reported adverse reaction for DOCETAXEL ANHYDROUS, manufactured by Hospira, Inc.. There are 16,937 FDA adverse event reports linking DOCETAXEL ANHYDROUS to ALOPECIA. This represents approximately 11.1% of all 152,096 adverse event reports for this drug.
Patients taking DOCETAXEL ANHYDROUS who experience alopecia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ALOPECIA is a frequently reported adverse event for DOCETAXEL ANHYDROUS, accounting for a significant proportion of all reports.
In addition to alopecia, the following adverse reactions have been reported for DOCETAXEL ANHYDROUS:
The following drugs have also been linked to alopecia in FDA adverse event reports:
ALOPECIA has been reported as an adverse event in 16,937 FDA reports for DOCETAXEL ANHYDROUS. This does not prove causation, but indicates an association observed in post-market surveillance data.
ALOPECIA accounts for approximately 11.1% of all adverse event reports for DOCETAXEL ANHYDROUS, making it one of the most commonly reported side effect.
If you experience alopecia while taking DOCETAXEL ANHYDROUS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.